Family Vaccine Protection Act
- Sponsor
- Sen. Hickenlooper, John W. [D-CO]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Mar 19, 2026
Bottom line
The Family Vaccine Protection Act aims to strengthen the independence and transparency of the nation's vaccine recommendation process by codifying ACIP and formalizing its relationship with the CDC Director.
What it actually does
This bill codifies the Advisory Committee on Immunization Practices (ACIP) within the Public Health Service Act, formalizing its role in providing vaccine recommendations to the Centers for Disease Control and Prevention (CDC) Director. It establishes specific procedures for how the CDC Director must review and either adopt or reject ACIP recommendations, requiring public justification and congressional notification for any rejection or action contrary to ACIP advice. The bill also mandates specific evidence standards for ACIP's recommendations and authorizes funding for its operations.
Proponents argue
Supporters argue that codifying ACIP ensures its continued operation and reinforces its scientific independence, protecting public health recommendations from political interference. They contend that requiring the CDC Director to publicly justify any deviation from ACIP's evidence-based recommendations increases transparency and public trust in vaccine guidance. Formalizing the process for considering new vaccines and applying rigorous evidence standards will lead to more consistent and reliable public health policy.
Opponents contend
Critics might argue that codifying ACIP could reduce flexibility for the CDC Director to respond quickly to evolving public health crises or to integrate broader public health considerations beyond ACIP's specific scientific scope. Some may also contend that the detailed procedural requirements could create bureaucratic hurdles, potentially delaying critical vaccine recommendations or responses during emergencies.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its provisions within a reasonable timeframe.
Section 2(a), inserting new Section 222A(a)-(d) into the Public Health Service Act.
Formalizing the Advisory Committee on Immunization Practices
This provision legally establishes the Advisory Committee on Immunization Practices (ACIP) within federal law, rather than it existing solely as an administrative body. It outlines ACIP's core duty to provide scientific advice and recommendations to the CDC Director on vaccine use for preventing diseases in the U.S. civilian population. It also specifies that ACIP's recommendations will be used for insurance coverage mandates (ACA Section 2713) and the Vaccines for Children Program.
Supporters argue
Supporters argue that codifying ACIP strengthens its institutional standing, ensuring its critical role in public health is permanently recognized and protected from administrative changes. This formalization enhances the stability and authority of vaccine recommendations, which are vital for public trust and effective disease prevention.
Critics contend
No specific opposition is typically raised against the general codification of an established scientific advisory body, as it often enhances transparency and accountability. However, some might express concern if the codification were perceived to overly restrict future administrative flexibility.
Tradeoffs
The primary tension is between maintaining administrative flexibility for public health agencies and ensuring the independence and stability of scientific advisory bodies. Codification leans towards stability and independence.
Section 2(a), inserting new Section 222A(c)(2) and (c)(5) into the Public Health Service Act.
Mandated Transparency for Vaccine Recommendation Decisions
This provision requires the CDC Director to adopt ACIP recommendations unless they are not supported by a "preponderance of the best available, peer-reviewed scientific evidence." If the Director chooses not to adopt a recommendation, or if the Secretary/Director takes an action contrary to ACIP's advice (e.g., on insurance coverage or VFC listing), they must publicly explain their reasoning, detailing why their decision *is* supported by the evidence, and notify relevant Congressional committees within 48 hours.
Section 2(a), inserting new Section 222A(d)(4) and (d)(5) into the Public Health Service Act; and Section 3, amending Section 2114(c) of the Public Health Service Act.
Rigorous Scientific Evidence Requirements
The bill mandates that ACIP, when making, revising, or withdrawing vaccine recommendations, must review evidence across specific categories, including study design strength, randomized controlled trials, and assessment of vaccine efficacy and safety. Additionally, any changes to the National Vaccine Injury Table, such as removing a vaccine or adding injuries, must be supported by a "preponderance of the best available scientific evidence."
If fewer than a quorum of ACIP's voting members are eligible to vote due to absence or conflict of interest, the Designated Federal Officer (DFO) or their designee has the authority to temporarily designate the non-voting ex-officio members as voting members.
Section 2(a), inserting new Section 222A(g)(5) into the Public Health Service Act.
Why it matters:This is standard legislative practice for ensuring the functionality of advisory committees even when unforeseen circumstances (like conflicts of interest or absences) might otherwise prevent a quorum. It's a practical mechanism to avoid paralysis.
Case for: Proponents would argue this ensures ACIP can always conduct its business and make timely recommendations, even if a significant number of its appointed members are unavailable or recused. This prevents procedural roadblocks from delaying critical public health guidance.
Case against: Critics might argue that temporarily converting non-voting ex-officio members (who represent specific federal agencies) into voting members could dilute the independence of ACIP's scientific recommendations by giving agency representatives direct voting power in certain scenarios, potentially introducing policy considerations over purely scientific ones.
Estimated impact: This provision could significantly alter the composition and voting dynamics of ACIP in specific, infrequent circumstances, potentially shifting the balance of scientific expertise versus agency representation in critical votes.
The bill states that Chapter 10 of Title 5, United States Code (the Federal Advisory Committee Act, FACA) applies to ACIP, "other than section 1013." Section 1013 of FACA generally mandates the termination of advisory committees after a certain period (typically two years) unless renewed. By excluding this section, the bill makes ACIP a permanent, rather than temporary, advisory committee.
Section 2(a), inserting new Section 222A(b) into the Public Health Service Act.
Why it matters:This is a common legislative technique to establish permanent advisory bodies without explicitly stating "ACIP is hereby made permanent" in a more prominent section. It's a technical way to achieve a significant structural change.
Case for: Proponents would argue that ACIP's role in public health is continuous and essential, making a permanent status appropriate. This avoids the administrative burden and potential disruption of periodic reauthorization, ensuring long-term stability for vaccine recommendations.
Case against: Critics might argue that requiring periodic reauthorization (as FACA generally mandates) provides an opportunity for regular congressional review and oversight of advisory committees, ensuring they remain relevant and effective. Making ACIP permanent removes this built-in review mechanism.
Estimated impact: This provision ensures the perpetual existence of ACIP, removing the need for regular legislative action to renew its charter.